Physician profile
Iveth Mastrapa
NPI 1891343661
$1,447.34
in general payments reported to CMS, 2019-2025
17 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $374 · 2022: $66.46 · 2023: $287 · 2024: $279 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $627.88 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $157.74 | 2021-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $118.69 | 2021-2025 | Rybelsus, Ozempic |
| Amgen INC. | $82.15 | 2023-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $59.12 | 2021 | |
| Lilly USA, LLC | $51.35 | 2021-2025 | Jardiance |
| Renalytix Ai, INC. | $46.87 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Bayer Healthcare Pharmaceuticals INC. | $43.66 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.09 | 2021-2024 | Jardiance |
| Shield Therapeutics INC | $38.99 | 2023-2025 | Accrufer |
| Pfizer INC. | $36.55 | 2021 | |
| Astellas Pharma US INC | $34.43 | 2025 | Veozah |
| Exact Sciences Corporation | $30.12 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $27.41 | 2021 | |
| Acadia Pharmaceuticals INC | $22.67 | 2024 | Daybue |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.08 | 2023 | |
| Abbvie INC. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iveth Mastrapa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.